Abingdon Health plc announced the launch, initially for research use only, of a score-card product available alongside the AbC-19 rapid test, which provides a semi-quantitative result to indicate the strength of antibody response and possible immunity. This is achieved by the use of a simple line intensity score-card as illustrated here which is available as an accessory to the standard Lateral Flow device ("LFD") for research applications. The AbC-19 LFD produces a line in the presence of IgG neutralising antibodies to the spike protein of the SARS-CoV-2 virus as are produced both after vaccination and natural infection. The intensity of the line, which can be seen visually, is proportional to the amount of these IgG neutralising antibodies present in the finger-prick blood sample with higher levels of antibodies producing a stronger test line. The use of the score-card has been referred to in studies, including one from the University of Birmingham, illustrating the use of the AbC-19 LFD in semi-quantitative format and showing the test line response to be proportional to the amount of antibodies in an international standard. The use of the score-card accessory alongside AbC-19 LFD will allow scientific communities to help further understand the presence and strength of IgG neutralising antibodies following infection and/or vaccination, a key indicator of protective immune response and an additional tool to allow stratification of patients in need of booster vaccinations. Abingdon Health is preparing the CE-marking of this scorecard accessory for the AbC-19 LFD and ultimately, when the scientific community determines the level of antibodies which infer immunity, has the potential to add a 'cut-off' to the score-card. Recent research has highlighted that immuno-compromised individuals generate lower levels of antibodies compared with healthier people following two vaccine doses, and there are variations in vaccine-response between males and females. A study published on 30 August 2021 highlighted different responses in patient cohorts when comparing the Moderna and Pfizer-BioNTech vaccines, with one study noting antibody levels start to reduce at around 2-3 months. Determining the presence and strength of IgG neutralising antibodies enables governments, individuals and businesses to make more informed decisions about COVID-safety measures and vaccine programme deployment to the most vulnerable. In areas of scarce vaccine supply IgG neutralising antibody testing could be deployed to stratify the population and direct vaccine to those with no or limited immunity to the SARS-CoV-2 virus. Abingdon Health notes the growing number of administrations such as Hong Kong that are now utilising post-vaccine serology testing, in Hong Kong's case with a view to shortening quarantine measures for inbound travellers and the Company believes that the addition of the Semi-Quantitative scorecard accessory will aid further deployment of on-site serology tests such as AbC-19.